Piramal Enterprises Limited

Piramal Life Sciences Limited

Council of Scientific and Industrial Research

Somesh Sharma

Swati Bal-Tembe

Sapna Parikh

Ravindra Dattatraya Gupte

Asha Adrian Kulkarni-Almeida

Ashish Suthar

Kalpana Sanjay Joshi

Vijay Singh Chauhan

Bansi Lal

Ashok Kumar Gangopadhyay

Maggie Rathos

Usha Ghosh

Tulsidas More

Nilesh Dagia

Radha Bhaskar Panicker

Aditi Amol Tannu

Shruta Sudheer Dadarkar

Mahesh Gundaji Jadhav

Ram Asrey Vishwakarma

Sanjay Kumar

Prathama Satyendra Mainkar

Meenakshi Sivakumar

Vijaykumar Bhagwan Deore

Muralidhara Padigaru

Nabajyoti Deka

Rosalind Adaikalasamy Marita

Anagha Damre

Dhananjay Sapre

Pramod Bhaskar Kumar

Chandrasekhar Srivari

Shashikant Patil

Sunil Jadhav

Ankush Gangaram Sarde

Pravin Gagare

Chada Raji Reddy

Srigiridhar Kotamraju

Pavan Kumar Togapur

Ramswaroop Mundada

Vilas Wagh

Ashok Kumar Jha

Prem Kumar Arumugam

Kavita Salkar

Sandip Kedar

Valmik Sopan Aware

Nikhil Krishnamurthy Hebbar

Harshal Khanwalkar

Subbarao Mohan Venkata Muppidi

Sujit Kaur Bhumra

Aditya Kelkar

Kumar Venkata Subrahmanya Nemmani

Aditee Ghate

Jessy Anthony

Pramod Kumar

Subbarao Mohan Muppidi

Amit Deshpande

Vilas Sampatrao Wagh

Arvind Thakkar

Sapna Hasit Parikh

Anandharajan Rathina Sabapathy

Sulfonyl hydroxamic acid compounds have the following general formula: Ring A and B are aryl, heteroaryl, cycloalkyl, fused aryl or fused alkyl group, and R, R, R, R, R, and Rare hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, or aldehyde. The compounds are HDAC inhibitors. Processes can be used for preparation of these indole-based sulfonyl hydroxamic acid derivatives.

Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors

The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.

Method of treatment for acne and an anti-acne formulation

A process for preparing an extract of, including: a) preparing crude juice; b) filtering to obtain filtered juice; c) modifying pH; d) allowing the pH modified juice to stabilize; e) neutralizing the stabilized juice; f) allowing the neutralized juice to stand for 20-30 minutes; g) rechecking the pH level; and h) drying the juice to obtain the extract. The process said above is simple, cost effective, which does not employ any harmful organic solvents and which enhances the potency of the constituents. A simple and potent formulation showing anti-diabetic activity comprising active constituents ofis also provided.

Process for preparation of a herbal extract

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer

A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination.

Synergistic pharmaceutical combination for the treatment of cancer

The present invention provides the compounds of formula (I): The present invention relates to imidazo[4,5-c]quinoline derivatives of formula (I), process for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PBK) and/or mammalian target of rapamycin (mTOR) and/or tumor necrosis factor-&#x3b1; (TNF-oc) and/or interleukin-6 (IL-6), particularly in the treatment of cancer and inflammation.

Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant,. The said extract ofcontains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor-(TNF-&#x3b1;) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1), vascular-cell adhesion molecule 1 (VCAM-1), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti-inflammatory agent.

Herbal composition for inflammatory disorders

Compounds of formula 1: are disclosed, wherein V is CH; W is S(O); m is the integer 0, 1 or 2; U is O, C(O), CRRor NR; where Ris H, alkyl; Ris H, OH, ORor OCOR; Ris H, alkyl, cycloalkyl, alkenyl, C(O)R, C(O)ORor alkylaminocarbonyl; R, R, R, R, R, R, Rand Rare as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-&#x3b1;) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-&#x3b1; activity, in particular inflammations.

Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

A herbal composition comprising a therapeutically effective amount of the extract ofleaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec&#xae; or Glivec&#xae;).

Herbal composition and process for its preparation

Fused tricyclic compounds as inhibitors of tumor necrosis factor-&#x3b1;

Growing community of inventors

Mumbai, India

Somesh Sharma